Premium
Letter: the feasibility and safety of accelerated infliximab infusions in patients with inflammatory bowel disease
Author(s) -
Nantes Ó.,
Rodríguez C.,
Basterra M.,
Gómez M.,
Cambra K.,
Ibáñez B.,
FernandezUrien I.,
Arín A.
Publication year - 2014
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.12607
Subject(s) - medicine , infliximab , adverse effect , intravenous infusions , inflammatory bowel disease , surgery , disease , anesthesia